The latest price target for Precision BioSciences (NASDAQ:DTIL) was reported by BMO Capital on January 10, 2025. The analyst firm set a price target for $34.00 expecting DTIL to rise to within 12 months (a possible 603.28% upside). 9 analyst firms have reported ratings in the last year.

The latest analyst rating for Precision BioSciences (NASDAQ:DTIL) was provided by BMO Capital, and Precision BioSciences upgraded their outperform rating.

The last upgrade for Precision BioSciences Inc happened on January 10, 2025 when BMO Capital raised their price target to $34. BMO Capital previously had a market perform for Precision BioSciences Inc.

The last downgrade for Precision BioSciences Inc happened on March 14, 2023 when BMO Capital changed their price target from $7 to $4 for Precision BioSciences Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Precision BioSciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Precision BioSciences was filed on January 10, 2025 so you should expect the next rating to be made available sometime around January 10, 2026.

While ratings are subjective and will change, the latest Precision BioSciences (DTIL) rating was a upgraded with a price target of $34.00 to $34.00. The current price Precision BioSciences (DTIL) is trading at is $4.83, which is out of the analyst’s predicted range.